Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowan-Jacob, Sandra W., Fendrich, Gabriele, Floersheimer, Andreas, Furet, Pascal, Liebetanz, Janis, Rummel, Gabriele, Rheinberger, Paul, Centeleghe, Mario, Fabbro, Doriano, Manley, Paul W.
Formato: Texto
Lenguaje:English
Publicado: International Union of Crystallography 2006
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483489/
https://www.ncbi.nlm.nih.gov/pubmed/17164530
http://dx.doi.org/10.1107/S0907444906047287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483489/
https://www.ncbi.nlm.nih.gov/pubmed/17164530
http://dx.doi.org/10.1107/S0907444906047287

Ejemplares similares